Anti-HDV+/HBeAg− (n = 37) | Anti-HDV+/HBeAg+ (n = 2) | Anti-HDV−/HBeAg− (n = 116) | Anti-HDV−/HBeAg+ (n = 45) | p Value | |
Patient characteristics | |||||
Male (%) | 76 | 100 | 90 | 87 | NS |
Age (years) | 34 (13–62) | 25 (23–28) | 49 (23–75) | 47 (11–78) | 0.0001 |
Source of infection | |||||
Household contact | 4 (11) | 1 (50) | 1 (1) | 1 (2) | 0.004 |
Vertical transmission | 1 (3) | 0 | 3 (3) | 2 (4) | |
Sexual transmission | 0 | 0 | 5 (4) | 6 (13) | |
Medical exposure | 2 (5) | 0 | 2 (2) | 3 (7) | |
Blood transfusion | 1 (3) | 0 | 2 (2) | 3 (7) | |
Drug addiction | 2 (5) | 1 (50) | 1 (1) | 0 | |
Unknown | 27 (73) | 0 | 102 (87) | 30 (67) | |
Biochemistry | |||||
AST:ALT ratio | 0.8 (0.19–1.54) | 0.65 (0.48–0.82) | 0.86 (0.19–2.94) | 0.72 (0.09–2.14) | NS |
Bilirubin (μmol/l) | 15 (5.9–35.7) | 14.2 (13–15.4) | 14 (5–51) | 13.6 (2.3–38.5) | NS |
Albumin (g/l) | 41 (29–48) | 45.5 (43–48) | 40 (25–52.4) | 41 (27.3–53.3) | NS |
γ-globulin (g/l) | 21 (9–46) | 19 (12–26) | 16 (7–39.7) | 16.8 (7.9–38) | 0.012 |
Platelets (109/l) | 131 (38–276) | 238 (216–261) | 150 (31–340) | 160 (68–287) | NS |
For statistical analysis, three groups were considered: anti-HDV+/HBeAg−, anti-HDV−/HBeAg−, and anti-HDV−/HBeAg+.
p Value derived from analysis of variance or χ2 test.
Data are expressed as median (range) or as number of patients (%).
anti-HDV, antibody to HDV; NS, non significant; ALT, alanine aminotransferase; AST, aspartate aminotransferase.